[Clinical utility of bone markers in the assessment of fracture risk].
Ichimura
Shoichi
S
Department of Orthopaedic Surgery, Kyorin University.
Satomi
Kazuhiko
K
D000135:Acid Phosphatase / Q000032:analysis; D000469:Alkaline Phosphatase / Q000032:analysis*; D000596:Amino Acids / Q000032:analysis*; D015415:Biomarkers / Q000032:analysis; D016723:Bone Remodeling; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D024042:Collagen Type I / Q000032:analysis*; D050723:Fractures, Bone / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D007527:Isoenzymes / Q000032:analysis; D015675:Osteocalcin / Q000032:analysis; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D010455:Peptides / Q000032:analysis*; D012306:Risk; D018570:Risk Assessment; D000071681:Tartrate-Resistant Acid Phosphatase
D000596:Amino Acids; D015415:Biomarkers; D024042:Collagen Type I; D007527:Isoenzymes; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; C036020:deoxypyridinoline; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase